Biotransformation of valdecoxib by microbial cultures

Journal of Microbiology and Biotechnology

Volumn 20, Issue 4, 2010, Pages 809-816

  Srisailam, K ^a   Veeresham, C ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

Biotransformation; HPLC; LC MS MS; Metabolites; Microbial; Valdecoxib

Indexed keywords

CARBOXYLIC ACID; DRUG METABOLITE; VALDECOXIB;

ARTICLE; BACTERIUM CULTURE; CARBOXYLATION; CONTROLLED STUDY; DEMETHYLATION; DIODE; DRUG ACETYLATION; DRUG HYDROXYLATION; DRUG TRANSFORMATION; FUNGUS CULTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLITE; MICROBIAL METABOLISM; NONHUMAN; PREDICTION; TANDEM MASS SPECTROMETRY; YEAST;

BACTERIA; CHROMATOGRAPHY, LIQUID; CYCLOOXYGENASE 2 INHIBITORS; FUNGI; ISOXAZOLES; SULFONAMIDES; TANDEM MASS SPECTROMETRY;

BACTERIA (MICROORGANISMS); FUNGI; MAMMALIA;

EID: 77954960284     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.0910.10027     Document Type: Article

References (30)

1. Abel, A. M., A. J. Carnell, J. A. Davis, and M. Paylor. 2003. The synthesis of buprenorphine intermediates by regioselective microbial N- and O-demethylation reactions using Cunninghamella echinulata NRRL 1384. Enzyme Microb. Technol. 33: 743-748.
2. Abourashed, E. A., A. M. Clark, and C. D. Hufford. 1999. Microbial models of mammalian metabolism of xenobiotics: An updated review. Curr. Med. Chem. 6: 359-374.
3. Camu, F., T. Beecher, D. P. Recker, and K. M. Verburg. 2002. Valdecoxib, a COX-2 specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am. J. Ther. 9: 43-51.
4. Clark, A. M. and C. D. Hufford. 1991. Use of microorganisms for the study of drug metabolism - An update. Med. Res. Rev. 11: 473-501.
5. Clark, A. M., J. D. McChesney, and C. D. Hufford. 1985. The use of microorganisms for the study of drug metabolism. Med. Res. Rev. 5: 231-253.
6. Dodge, R. H., C. E. Cerniglia, and D. T. Gibson. 1979. Fungal metabolism of biphenyl. Biochem. J. 178: 223-230.
7. Duhart, B. T., D. Zhang, J. Deck, J. P. Freeman, and C. E. Cerniglia. 1999. Biotransformation of protriptyline by filamentous fungi and yeasts. Xenobiotica 29: 733-746.
8. Ferris, J. P., M. J. Fasco, F. L. Stylianopoulou, D. M. Jerina, J. W. Daly, and A. M. Jeffrey. 1973. Monooxygenase activity in Cunninghamella bainieri: Evidence for a fungal system similar to liver microsomes. Arch. Biochem. Biophys. 156: 97-103.
9. Foster, B. C., D. L. Wilson, and I. J. McGilveray. 1989. Effect of sparteine and quinidine on the metabolism of methoxyphenamine by Cunninghamella bainieri. Xenobiotica 19: 445-452.
10. Foster, G. R., R. T. Coutts, F. M. Pasutto, and A. Mozayani. 1988. Microbial metabolism of phenelzine and pheniprazine. Life Sci. 42: 285-292.
11. Foster, G. R., D. L. Lister, J. Zamecnic, and R. T. Coutts. 1991. The biotransformation of tranylcypromine by Cunninghamella echinulata. Can. J. Microbiol. 37: 791-795.
12. Freitag, D. G., R. T. Foster, R. T. Coutts, M. A. Pickard, and F. M. Pasutto. 1997. Stereoselective metabolism of rac-mexiletine by the fungus Cunninghamella echinulata yields the major mammalian metabolites hydroxymethylmexiletine and p-hydroxymexiletine. Drug Metab. Dispos. 25: 685-692.
13. Gessel, M., E. Hammer, M. Specht, W. Francke, and F. Schauer. 2001. Biotransformation of biphenyl by Paecilomyces lilacinus and characterization of ring cleavage products. Appl. Environ. Microbiol. 67: 1551-1557.
14. Golbeck, J. H., S. A. Albaugh, and R. Radmer. 1983. Metabolism of biphenyl by Aspergillus toxicarius: Induction of hydroxylating activity and accumulation of water-soluble conjugates. J. Bacteriol. 156: 49-57.
15. Hansen Jr., E. B., R. H. Heflich, W. A. Korfmacher, D. W. Miller, and C. E. Cerniglia. 1988. Microbial transformation of the antihistamine drug triprolidine hydrochloride. J. Pharm. Sci. 77: 259-264.
16. Harris, R. R., L. Black, S. Surapaneni, T. Kolasa, S. Majest, M. T. Namovic, et al. 2004. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor. J. Pharmacol. Exp. Ther. 311: 904-912.
17. Huang, H., X. Yang, Q. Li, L. Sun, and D. Zhong. 2006. Biotransformation of tolbutamide to 4'-hydroxytolbutamide by the fungus Cunninghamella blakesleana. Appl. Microbiol. Biotechnol. 72: 486-491.
18. Keshetty, S., R. K. Venisetty, V. Molmoori, and V. Ciddi. 2006. Determination of valdecoxib in serum using HPLC-diode array detector and its application in pharmacokinetic study. Pharmazie 61: 245-246.
19. Mazier, C., M. Jaouen, M. Sari, and D. Buisson. 2004. Microbial oxidation of terfenadine and ebastine into fexofenadine and carebastine. Bioorg. Med. Chem. Lett. 14: 5423-5426.
20. Schwartz, H., A. Liebig-Weber, H. Hochstatter, and H. Bottcher. 1996. Microbial oxidation of ebastine. Appl. Microbiol. Biotechnol. 44: 731-735.
21. Smith, R. V., P. J. Davis, A. M. Clark, and S. Glover-Milton. 1980. Hydroxylation of biphenyl by fungi. J. Appl. Bacteriol. 49: 65-73.
22. h Midwest Regional Meeting of the American Chemical Society, St. Louis, Missouri.
23. Talley, J. J., D. L. Brown, J. S. Carter, M. J. Graneto, C. M. Koboldt, J. L. Masferrer, et al. 2000. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J. Med. Chem. 43: 775-777.
24. Talley, J. J., S. R. Bertenshaw, D. L. Brown, J. S. Carter, M. J. Graneto, M. S. Kellogg, et al. 2000. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J. Med. Chem. 43: 1661-1663.
25. Venisetty, R. K., S. Keshetty, and V. Ciddi. 2004. Optimization of surfactants and polymers to alter the morphology of matt forming fungal cultures, an improved way for fungal drug metabolism studies, Abstr. PB-P005, p. 282. Abstr. 6f FIP Congress, International Pharmaceutical Federation, New Orleans, U.S.A.
26. Vigne, B., A. Archelas, and R. Furstoss. 1991. Microbial transformations 18. Regiospecific para-hydroxylation of aromatic carbamate mediated by the fungus Beauveria sulfurescens. Tetrahedron 47: 1447-1458.
27. Wong, Y. W. J. and P. J. Davis. 1989. Microbial models of mammalian metabolism: Stereoselective metabolism of warfarin in the fungus Cunninghamella elegans. Pharm. Res. 6: 982-985.
28. Yuan, J. J., D. Yang, J. Y. Zhang, R. Bible Jr., A. Karim, and J. W. A. Findlay. 2002. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab. Dispos. 30: 1013-1021.
29. Zhang, D., H. Zhang, N. Aranibar, R. Hanson, Y. Huang, P. T. Cheng, et al. 2006. Structural elucidation of human oxidative metabolites of muraglitazar: Use of microbial bioreactors in the biosynthesis of metabolite standards. Drug Metab. Dispos. 34: 267-280.s
30. Zhang, J. Y., J. J. Yuan, Y. Wang, R. H. Bible Jr., and A. P. Breau. 2003. Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. Drug Metab. Dispos. 31: 491-501.